The Food and Drug Administration has awarded Engility (NYSE: EGL) a potential five-year, $112 million indefinite-delivery/indefinite-quantity contract to provide computational science and bioinformatics services for the FDA’s gene-based drug discovery and development programs.
Engility said Thursday it will help the FDA operate, secure and maintain scientific computing environments and systems designed to support rapid genomic analyses the agency conducts to understand personalized medicine-related adverse events and emerging threats to the U.S. food supply chain.
The company added it will develop high-performance computing architectures for the agency to analyze complex data sets under the contract.
“With this award, Engility expands on our long-standing partnership with the FDA to further develop their high performance computing and complex data analysis capabilities, ” said Lynn Dugle, Engility CEO.
“We look forward to supporting the FDA’s mission to make groundbreaking treatments, such as genetics-based medicine, available to all Americans, ” Dugle added.
Engility will also collaborate with FDA centers as well as the agency’s Office of Acquisition and Grants Services and Office of Information Management and Technology to integrate scientific computing methods into regulatory science and innovation efforts at the agency.